Freenome, Inc.
No SEC Form 4 filings for $FRNM in the last 30 days.
See all $FRNM insider activity →OmniAb (OABI) +13% to $5.43, raising 2026 cash flow guidance to $49M-$53M. Freenome (FRNM) +4% to $16.03 after FDA approvals. Exelixis (EXEL) +$59.11, Q2 profit $212M. LifeStance (LFST) +$13.15, Q2 revenue +26% to $435.4M. Faeth (FTH) +$40.89, Q2 loss $16M.
Aethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.
Jefferies initiated coverage on Freenome (FRNM) with a 'Buy' rating and $17 price target, citing its cancer detection tests and partnerships. Shares rose 12% to $13.00. Freenome's lead product, SimpleScreen, competes in colorectal cancer testing. The company plans to expand into other cancers, with lung cancer next. Key milestones include FDA approvals and a U.S. launch this fall. Freenome is unprofitable but has $1.3B market cap. Jefferies' target implies 47% upside from $11.56 close.
Over the past 7 days, alphai's AI scored 1 news story mentioning FRNM (Freenome, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent FRNM coverage spans market movers, mergers & acquisitions and corporate actions.
FDA clearance provides a clear commercial pathway, likely boosting sales and stock momentum.
Breakthrough designation accelerates regulatory timeline and may attract partnership interest.
Analyst initiation and a high price target provide a fresh bullish catalyst for FRNM.
This is a small positive flow signal for FRNM, without any accompanying fundamental update in the text.
Completion of the reverse recap and PIPE financing is a capital-structure and listing-status catalyst that can drive near-term repricing and liquidity changes.
alphai scores every news story that mentions FRNM with an AI model for sentiment and relevance, and aggregates insider trades from Freenome, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
OmniAb (OABI) +13% to $5.43, raising 2026 cash flow guidance to $49M-$53M. Freenome (FRNM) +4% to $16.03 after FDA approvals. Exelixis (EXEL) +$59.11, Q2 profit $212M. LifeStance (LFST) +$13.15, Q2 revenue +26% to $435.4M. Faeth (FTH) +$40.89, Q2 loss $16M.
2 min readAethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.
3 min readJefferies initiated coverage on Freenome (FRNM) with a 'Buy' rating and $17 price target, citing its cancer detection tests and partnerships. Shares rose 12% to $13.00. Freenome's lead product, SimpleScreen, competes in colorectal cancer testing. The company plans to expand into other cancers, with lung cancer next. Key milestones include FDA approvals and a U.S. launch this fall. Freenome is unprofitable but has $1.3B market cap. Jefferies' target implies 47% upside from $11.56 close.
3 min readInvesting.com reports Cathie Wood’s ARK ETFs published Thursday trades. ARK bought 106,941 shares of Cerebras Systems (CBRS) for about $28.0M and bought Securitize (SECZ) and Perceptive Capital Solutions (FRNM). It sold Shopify (SHOP) 57,045 shares for about $8.6M and sold Palantir (PLTR) for about $7.5M, plus other smaller trades.
3 min readFreenome, Inc. (FRNM) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.1 19 ef20078324_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K (the “Form 8-K”) filed with the Sec
6 min readPerceptive Capital Solutions Corp (PCSC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0002017526 0002017526 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July
2 min readPerceptive Capital Solutions Corp (PCSC) and Freenome Holdings said the SEC declared their joint Form S-4 registration statement effective on June 17, 2026 for their proposed business combination. PCSC’s extraordinary general meeting is scheduled for July 9, 2026, with a definitive proxy statement/prospectus mailed to shareholders of record June 12. The companies expect a July 2026 close, subject to conditions.
2 min readPerceptive Capital Solutions Corp (PCSC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 12-31 0002017526 0002017526 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
4 min read
